Daniel A. Briere

2.0k citations

18 papers · 1.2k indexed · 2 hit papers · h-index 13

Impact in

Endocrinology, Diabetes and Metabolism top 1%
- Diabetes Treatment and Management
Pharmacology top 5%
- Pharmacology and Obesity Treatment

Papers in

Endocrinology, Diabetes and Metabolism 12
- Diabetes Treatment and Management 11
Pharmacology 4
- Pharmacology and Obesity Treatment 3

Co-authors: Kyle W. Sloop Tamer Coşkun Ruth E. Gimeno Shweta Urva Axel Haupt Corina Loghin Charles Benson William C. Roell
Journals: Diabetes (4 papers)Molecular Metabolism (3 papers)Diabetes Obesity and Metabolism (2 papers)Cell Metabolism (2 papers)Journal of Medicinal Chemistry (2 papers)
Partner nations: United States Spain Germany

In The Last Decade

Daniel A. Briere

16 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept 2022 · 180 citations

Peers

Countries citing papers authored by Daniel A. Briere

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Briere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Briere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Briere more than expected).

Fields of papers citing papers by Daniel A. Briere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Briere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Briere. The network helps show where Daniel A. Briere may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel A. Briere, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel A. Briere Line = papers co-authored together Daniel A. Briere links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Diabetes Obesity and Metabolism ·М. А. Истомова, Р.С. Сауткин, 黄兴才, Yount Sm, Hongchang Qu, Daniel A. Briere, Issa Cissee, Kieren J. Mather, Edward Pratt	2026	0
2	Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Molecular Metabolism ·Daniel A. Briere, Hongchang Qu, Katherine Lansu, Minxia M. He, Julie S. Moyers, Tamer Coşkun, Andrew Long, David Allen, Libbey S. O′Farrell, Tony Roy Edward, Edward Pratt, László Marjanucz, Lai Tham, Yount Sm, Jorge Alsina‐Fernandez, Kieren J. Mather, Axel Haupt, Shobha Bhattachar	2025	4
3	849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide Diabetes ·Daniel A. Briere, A. Long, Mccubrey JA, Libbey S. O′Farrell, Tony Roy Edward, Katherine Lansu, Samrangy Sadhu, Julie S. Moyers, Hongchang Qu	2025	0
4	882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept Diabetes ·Shobha Bhattachar, Nina Bremm, László Marjanucz, Daniel A. Briere, Hongchang Qu, Axel Haupt, Edward Pratt, Kieren J. Mather	2025	2
5	LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism ·Tamer Coşkun, Shweta Urva, William C. Roell, Hongchang Qu, Corina Loghin, Julie S. Moyers, Libbey S. O′Farrell, Daniel A. Briere, Kyle W. Sloop, Melissa K. Thomas, Valentina Pirro, David B. Wainscott, Francis S. Willard, Jacqueline Maplesden, LaRonda L. Morford, Yu Du, Charles Benson, Ruth E. Gimeno, Axel Haupt, Zvonko Miličević Hit paper breakdown →	2022	180
6	GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior Diabetes ·Ricardo J. Samms, Richard Cosgrove, Winston Zamora, Michael Kammen, Brian A. Droz, Daniel A. Briere, James D. Dunbar, Mridula Dogra, Jorge Alsina‐Fernandez, Tito Borner, Bart C. De Jonghe, Matthew R. Hayes, Tamer Coşkun, Kyle W. Sloop, Paul J. Emmerson, Minrong Ai	2022	46
7	Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor Journal of Medicinal Chemistry ·Francis S. Willard, David B. Wainscott, Aaron D. Showalter, Cynthia Stutsman, Wenzhen Ma, Guemalli R. Cardona, Richard W. Zink, Kuba Karliński, Qi Chen, Nathan Yumibe, Javier Agejas, Graham R. Cumming, A. Siddons, Alma Jiménez, Marie Jeanne Charlotte Dry, Ana M. Castaño‐León, Daniel A. Briere, Kyle W. Sloop, Ana B. Bueno	2021	14
8	The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists Diabetes Obesity and Metabolism ·Shweta Urva, Tamer Coşkun, Corina Loghin, Xuewei Cui, Elena Malekkidou, Libbey S. O′Farrell, Daniel A. Briere, Charles Benson, Michael A. Nauck, Axel Haupt	2020	92
9	Leveraging the Gut to Treat Metabolic Disease Cell Metabolism ·Ruth E. Gimeno, Daniel A. Briere, Randy J. Seeley	2020	53
10	Compound 18 Improves Glucose Tolerance in a Hepatocyte TGR5-dependent Manner in Mice Nutrients ·Marlena M. Holter, Chiara Donati, Daniel A. Briere, Adriano Maida, Kyle W. Sloop, Kristina Schoonjans, Bethany P. Cummings	2020	17
11	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Molecular Metabolism ·Tamer Coşkun, Kyle W. Sloop, Corina Loghin, Jorge Alsina‐Fernandez, Shweta Urva, Krister Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Ritin Patel, Julie S. Moyers, Charles Benson, Ruth E. Gimeno, David A. D’Alessio, Axel Haupt Hit paper breakdown →	2018	603
12	GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function Molecular Metabolism ·Hua Lin, Jingru Wang, Jie Wang, W. Szaflik, Xuesong Wang, James T. Alston, Melissa K. Thomas, Daniel A. Briere, Samreen K. Syed, Alexander M. Efanov	2018	28
13	Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases? ACS Pharmacology & Translational Science ·Kyle W. Sloop, Daniel A. Briere, Paul J. Emmerson, Francis S. Willard	2018	26
14	Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery Diabetes ·Daniel A. Briere, Ana B. Bueno, M Munawir, M. Dodson Michael, Kyle W. Sloop	2017	46
15	Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice PLoS ONE ·Daniel A. Briere, Xiaoping Ruan, Christine C. Cheng, Angela M. Siesky, Thomas Fitch, Erik P. Simon, Thomas Shortt, Carlos Closa, Chen S. Suen, Yanping Xu, Tamer Coşkun, M. Dodson Michael	2015	66
16	Activation of Prostaglandin E Receptor 4 Triggers Secretion of Gut Hormone Peptides GLP-1, GLP-2, and PYY Endocrinology ·Tamer Coşkun, Libbey S. O′Farrell, Samreen K. Syed, Daniel A. Briere, Lisa S. Beavers, Susan L. DuBois, Iryna Avdiienko, Vishwadeepak Kimothi, David G. Barrett, Alexander M. Efanov	2012	16
17	Tetrahydroisoquinoline PPARγ agonists: Design of novel, highly selective non-TZD antihyperglycemic agents Bioorganic & Medicinal Chemistry Letters ·James R. Henry, Yihong Li, Alan M. Warshawsky, Joseph T. Brozinick, Eric D. Hawkins, Rindi Nathasya, Daniel A. Briere, Chahrzad Montrose‐Rafizadeh, Richard W. Zink, Nathan Yumibe, Rose T. Ajamie, Peter David Poole, Viswanath Devanarayan	2006	1
18	Novel Lavendamycin Analogues as Potent HIV-Reverse Transcriptase Inhibitors: Synthesis and Evaluation of Anti-Reverse Transcriptase Activity of Amide and Ester Analogues of Lavendamycin Journal of Medicinal Chemistry ·Mohammad Behforouz, Wen Cai, Syifa'ur Rohmah, J. M. Cei, 王佳一, Daniel A. Briere, Aiqin Wang, R. Lane, A. A. Z. Mendiburu	2003	26

About Daniel A. Briere

Daniel A. Briere is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology, Cellular and Molecular Neuroscience, Gastroenterology and Endocrine and Autonomic Systems, having authored 18 papers that have together received 1.2k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (11 papers), Neuropeptides and Animal Physiology (4 papers), Pharmacology and Obesity Treatment (3 papers), Receptor Mechanisms and Signaling (3 papers), Pancreatic function and diabetes (3 papers), Drug Transport and Resistance Mechanisms (2 papers), Helicobacter pylori-related gastroenterology studies (2 papers) and Metabolism, Diabetes, and Cancer (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (837 citations), Pharmacology (347 citations), Endocrine and Autonomic Systems (117 citations), Physiology (277 citations) and Cellular and Molecular Neuroscience (170 citations). Daniel A. Briere has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Kyle W. Sloop, Tamer Coşkun, Ruth E. Gimeno, Shweta Urva, Axel Haupt, Corina Loghin, Charles Benson, William C. Roell, Xuewei Cui and Julie S. Moyers. Their work appears in journals such as Diabetes, Molecular Metabolism, Diabetes Obesity and Metabolism, Cell Metabolism and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact